FDA conditionally approves drug for canine neuropathic painMay 13, 2026Liavium-CA1 is indicated for the management of pain and clinical signs associated with Chiari-like malformation and syringomyelia in dogs. The drug, with the active ingredient pregabalin, reduces the release of neurotransmitters that send pain signals in the spinal cord.
SPONSORED CONTENTWhere unique needs meet innovative scienceFind precise, innovative solutions for your patients’ unique needs + Learn More
